Patrys Limited (ASX:PAB) Filings

Patrys Limited

Filings

FilingDateTypeFiled with
Change of AuditorNov 11, 2026Management or board changeASX
Change in substantial holdingNov 9, 2026Ownership change noticeASX
Change of Director's Interest Notice x2Nov 9, 2026Ownership change noticeASX
Cleansing NoticeNov 9, 2026FinancingASX
Application for quotation of securities - PABNov 9, 2026FinancingASX
Letter to Shareholders - Annual General MeetingOct 29, 2026Meeting noticeASX
Notice of Annual General Meeting/Proxy FormOct 29, 2026Meeting noticeASX
Appendix 4C - Quarterly - 30 September 2026Oct 28, 2026Quarterly reportASX
Appendix 4C - Quarterly - 30 September 2026Oct 28, 2026Quarterly reportASX
RLS-2202 Phase 1a Trial Advances to Cohort 2Oct 21, 2026Other filingsASX
RLS-2202 Phase 1a Trial Advances to Cohort 2Oct 21, 2026Other filingsASX
Investor PresentationOct 12, 2026Other filingsASX
Investor WebinarOct 5, 2026Other filingsASX
Date of AGM and Closing Date for Director NominationsOct 5, 2026Meeting noticeASX
Notification of cessation of securities - PABSep 30, 2026FinancingASX
Patrys Completes Cohort 1 Dosing and Follow-UpSep 28, 2026Operations updateASX
Appendix 4E Variance ReportSep 28, 2026ResultsASX
Annual Report - 30 June 2025Sep 28, 2026Annual reportASX
Appendix 4G and Corporate Governance StatementSep 28, 2026Other filingsASX
First Participants Dosed in RLS-2202 Phase 1A Clinical TrialSep 22, 2026Other filingsASX
PAB Establishes Clinical Advisory CommitteeSep 16, 2026Operations updateASX
Appendix 4E - Preliminary Final ReportAug 31, 2026ResultsASX
Ethics Approval Secured for Phase 1A Clinical TrialAug 27, 2026Other filingsASX
Investor Presentation - TechKnow Invest RoadshowJul 26, 2026Other filingsASX
Appendix 4C - Quarterly - 30 June 2026Jul 21, 2026Quarterly reportASX
Patrys Secures 50% Revenue Share in IP CommercialisationJul 12, 2026Acquisition or disposalASX
Patrys advances RLS-2202 toward Phase 1 Clinical TrialMay 19, 2026Other filingsASX
Appendix 4C - Quarterly - 31 March 2026Apr 29, 2026Quarterly reportASX
$3.2 million Placement to Advance Clinical TrialsApr 19, 2026FinancingASX
Investor Presentation - Broker Meets BiotechMar 30, 2026Other filingsASX
RLS-2201 Manufacturing and Regulatory Pathway InitiatedMar 10, 2026Operations updateASX
Appendix 4D - Half Year Accounts - 31 December 2025Feb 26, 2026Interim reportASX
Appointment of Chief Executive OfficerFeb 11, 2026Management or board changeASX
Appendix 4C - Quarterly - 31 December 2025Jan 29, 2026Quarterly reportASX
Investor PresentationJan 27, 2026Acquisition or disposalASX
Completion of Acquisition and Board AppointmentsJan 27, 2026Acquisition or disposalASX
Pipeline Expanded with Proprietary Injectable AntipsychoticNov 25, 2025Acquisition or disposalASX
Trading HaltNov 23, 2025Trading halt or suspensionASX
Appendix 4C - Quarterly - 30 September 2025Oct 29, 2025Quarterly reportASX
Patrys Receives R&D Tax Incentive RefundOct 29, 2025FinancingASX
Notice of Annual General Meeting/Proxy FormSep 7, 2025Meeting noticeASX
Appendix 4E - Preliminary Final ReportAug 29, 2025Annual reportASX
Appendix 4C - Quarterly - 30 June 2025Jul 29, 2025Quarterly reportASX
Entitlement Offer ProspectusJul 23, 2025Offer documentASX
Non-Renounceable Entitlement OfferJul 23, 2025Offer documentASX
Deed of Release entered into with CEOJun 16, 2025Management or board changeASX
Successful Placement and Board ChangesJun 10, 2025FinancingASX
Reinstatement to Official QuotationJun 10, 2025Trading halt or suspensionASX
Suspension from QuotationJun 3, 2025Trading halt or suspensionASX
Appendix 4C - Quarterly - 31 March 2025Apr 30, 2025Quarterly reportASX
Appendix 4D - Half Year Accounts - 31 December 2024Feb 21, 2025Interim reportASX
Appendix 4C - Quarterly - 31 December 2024Jan 29, 2025Quarterly reportASX
Appendix 4C - Quarterly - 30 September 2024Oct 29, 2024Quarterly reportASX
PAT-DX1 clinical development updateOct 1, 2024Other filingsASX
PAT-DX1 GMP specification testing updateSep 19, 2024Other filingsASX
Appendix 4E and 2024 Annual ReportAug 23, 2024Annual reportASX
Further update on PAT-DX1 GMP manufacturing runJul 28, 2024Other filingsASX
Appendix 4C - Quarterly - 30 June 2024Jul 23, 2024Quarterly reportASX
Update on GMP manufacturing run of PAT-DX1Jun 30, 2024Other filingsASX
Appendix 4C - Quarterly - 31 March 2024Apr 29, 2024Quarterly reportASX
Positive preclinical data for deoxymabs in vasculitisApr 8, 2024Operations updateASX
Appendix 4D - Half Year Accounts - 31 December 2023Feb 23, 2024Interim reportASX
Appendix 4C - Quarterly - 31 December 2023Jan 22, 2024Quarterly reportASX
GMP Production of PAT-DX1 Next QuarterDec 12, 2023Operations updateASX
Appendix 4C - Quarterly - 30 September 2023Oct 19, 2023Quarterly reportASX
Appendix 4E and 2023 Annual ReportAug 28, 2023Annual reportASX
Appendix 4C - Quarterly - 30 June 2023Jul 25, 2023Quarterly reportASX
PAT-DX1 GLP toxicology reports receivedMay 23, 2023Other filingsASX
Appendix 4C - Quarterly - 31 March 2023Apr 24, 2023Quarterly reportASX
Two new deoxymab patents granted in the USAApr 16, 2023Other filingsASX
Updated guidance for PAT-DX1 phase 1 clinical studyMar 30, 2023GuidanceASX
New PAT-DX3 data demonstrates synthetic lethalityMar 13, 2023Other filingsASX
Appendix 4D - Half Year Accounts - 31 December 2022Feb 24, 2023Interim reportASX
Appendix 4C - Quarterly - 31 December 2022Jan 30, 2023Quarterly reportASX
Response to ASX Price QueryDec 14, 2022Explanation requestASX
Appendix 4C - Quarterly - 30 September 2022Oct 27, 2022Quarterly reportASX
PAT DX3 Crosses Blood Brain Barrier in Healthy AnimalsOct 16, 2022Other filingsASX
Appendix 4E and 2022 Annual ReportAug 30, 2022Annual reportASX
PAT-DX1 From Engineering Run Meets all Specification TestsAug 29, 2022Other filingsASX
New Research Grant For Deoxymabs in Metastatic Breast CancerAug 26, 2022Other filingsASX
PAT-DX1/Radiation Combination Improves Brain Cancer SurvivalAug 9, 2022Other filingsASX
Appendix 4C - Quarterly - 30 June 2022Jul 27, 2022Quarterly reportASX
PAT-DX1 Engineering Run Successfully CompletedJul 3, 2022Other filingsASX
New Mechanism By Which PAT-DX1 May Reduce Cancer MetastasisJun 13, 2022Other filingsASX
CBCF funding to support deoxymab brain cancer developmentJun 3, 2022Other filingsASX
Appendix 4C - Quarterly - 31 March 2022Apr 28, 2022Quarterly reportASX
Stable Cell Line for Production of PAT-DX3 EstablishedFeb 27, 2022Other filingsASX
Appendix 4D - Half Year Accounts - 31 December 2021Feb 24, 2022Interim reportASX
Appendix 4C - Quarterly - 31 December 2021Jan 30, 2022Quarterly reportASX
PAT-DX1 engineering updateJan 23, 2022Other filingsASX
Rights Issue Results and Shortfall NotificationDec 2, 2021FinancingASX
Rights Issue Offer DocumentNov 8, 2021FinancingASX
$7.8M Capital RaisingOct 31, 2021FinancingASX
Appendix 4C - Quarterly - 30 September 2021Oct 19, 2021Quarterly reportASX
Patrys proof of concept ADC significantly increases survivalOct 17, 2021Other filingsASX
PAT-DX3 proof of concept as potential ADC targeting antibodySep 14, 2021Other filingsASX
Appendix 4E and 2021 Annual ReportAug 25, 2021Annual reportASX
Market Update - PAT-DX1 Clinical Trial PreparationAug 2, 2021Other filingsASX
Appendix 4C - Quarterly - 30 June 2021Jul 29, 2021Quarterly reportASX
PAT-DX1 Improves Survival in Model of Pancreatic CancerJul 25, 2021Other filingsASX
Full size deoxymab PAT-DX3 crosses the blood brain barrierJul 11, 2021Other filingsASX
Response to ASX QueryJun 23, 2021Explanation requestASX
Paper highlights PAT-DX1 as potential brain cancer treatmentJun 15, 2021Other filingsASX
Patrys receives R&D Tax Incentive refundJun 9, 2021Other filingsASX
Appendix 4C - Quarterly - 31 March 2021Apr 27, 2021Quarterly reportASX
New United States patent granted for Patrys deoxymab assetsMar 30, 2021Other filingsASX
Appendix 4D - Half Year Accounts - 31 December 2020Feb 19, 2021Interim reportASX
Patrys Successfully Establishes PAT-DX1 Stable Cell LineFeb 9, 2021Other filingsASX
Appendix 4C - Quarterly - 31 December 2020Jan 27, 2021Quarterly reportASX
$7.3M Capital RaisingNov 8, 2020FinancingASX
Investor Presentation - November 2020 - UpdatedNov 5, 2020Other filingsASX
Investor Presentation - November 2020Nov 4, 2020Other filingsASX
Appendix 4C - Quarterly - 30 September 2020Oct 25, 2020Quarterly reportASX
First patent granted for Deoxymab-nanoparticlesOct 5, 2020Other filingsASX
Patrys adds full human antibody to Deoxymab portfolioSep 27, 2020Other filingsASX
Appendix 4E and 2020 Annual ReportAug 24, 2020Annual reportASX
Appendix 4C - Quarterly - 30 June 2020Jul 30, 2020Quarterly reportASX
$4.29 Million Fully Underwritten Rights IssueJun 22, 2020FinancingASX
Investor Presentation - June 2020Jun 17, 2020Other filingsASX
Appendix 4C - Quarterly - 31 March 2020Apr 26, 2020Quarterly reportASX
PAT-DX1 mechanism for crossing blood brain barrier confirmedMar 15, 2020Other filingsASX
PAT-DX1-NP crosses BBB and targets tumoursMar 1, 2020Other filingsASX
Appendix 4D - Half Year Accounts - 31 December 2019Feb 24, 2020Interim reportASX
Appendix 4C - Quarterly - 31 December 2019Jan 29, 2020Quarterly reportASX
Appendix 4C - Quarterly - 30 September 2019Oct 28, 2019Quarterly reportASX
Appendix 4E and 2019 Annual ReportAug 22, 2019Annual reportASX
Appendix 4C - Quarterly - 30 June 2019Jul 29, 2019Quarterly reportASX
PAT-DX1 significantly improves survival in aggressive GBMJul 21, 2019Other filingsASX
Europe grants patent for Deoxymab 3E10Jul 17, 2019Other filingsASX
PAT-DX1 Reduces Brain Metastases, Enhances Radiation TherapyMay 29, 2019Other filingsASX
Appendix 4C - Quarterly - 31 March 2019Apr 23, 2019Quarterly reportASX
Market UpdateMar 29, 2019Other filingsASX
Appendix 4D - Half Year Accounts - 31 December 2018Feb 20, 2019Interim reportASX
Appendix 4C - Quarterly - 31 December 2018Jan 30, 2019Quarterly reportASX
PAT-DX1 Suppresses Breast Cancer Brain MetastasesDec 19, 2018Other filingsASX
Appendix 4C - Quarterly - 30 September 2018Oct 30, 2018Quarterly reportASX
Settlement of Manufacturing ClaimsOct 24, 2018Other filingsASX
PAT-DX1 Clinical Target Indications ConfirmedOct 4, 2018Other filingsASX
Patrys and WEHI Awarded GrantAug 28, 2018Other filingsASX
Appendix 4E and 2018 Annual ReportAug 24, 2018Annual reportASX
Patent Granted for Pre-clinical IgM Candidate PAT-LM1Aug 1, 2018Other filingsASX
Appendix 4C - Quarterly - 30 June 2018Jul 25, 2018Quarterly reportASX
Preliminary PAT-DX1 pharmacokineticsJul 5, 2018Other filingsASX
China and Japan both grant patents for Deoxymab 3E10Jul 3, 2018Other filingsASX
PAT-DX1 Targets and Kills Brain Cancer Stem CellsMay 30, 2018Other filingsASX
Patrys Increases Capital Raising to $4.6 millionMay 20, 2018FinancingASX
New Pre-Clinical Collaboration on PAT-DX1May 16, 2018Other filingsASX
Patrys Completes $3.5M PlacementMay 15, 2018FinancingASX
Appendix 4C - Quarterly - 31 March 2018Apr 26, 2018Quarterly reportASX
PAT-DX1 Improves Survival in Animal Model of GlioblastomaMar 18, 2018Other filingsASX
PAT-DX1 Crosses Blood Brain Barrier to Reduce Tumour SizeFeb 27, 2018Other filingsASX
Appendix 4D - Half Year Accounts - 31 December 2017Feb 23, 2018Interim reportASX
Appendix 4C - Quarterly - 31 December 2017Jan 31, 2018Quarterly reportASX
Publication and Patent Filing for Humanized Version of 3E10Jan 30, 2018Other filingsASX
PAT-DX1-NP Localizes to Lymph Node MetastasesJan 28, 2018Other filingsASX
Entitlement Offer BookletJan 14, 2018FinancingASX
PAT-DX1 is synergistic with PARP inhibitorDec 10, 2017Other filingsASX
Collaboration with WEHINov 15, 2017Other filingsASX
Appendix 4C - Quarterly - 30 September 2017Oct 27, 2017Quarterly reportASX
PAB and Garvan Institute of Medical Research Awarded GrantOct 15, 2017Other filingsASX
US Patent Granted for Preclinical Candidate PAT-LM1Oct 11, 2017Other filingsASX
PAT-DX1 Conjugated to Nanoparticles, Targets TumorsSep 17, 2017Other filingsASX
PAT-DX1 Active in Pre-clinical Cancer ModelsSep 13, 2017Other filingsASX
Appendix 4E and 2017 Annual ReportAug 29, 2017Annual reportASX
Appendix 4C - Quarterly - 30 June 2017Jul 26, 2017Quarterly reportASX
Patrys Deoxymab 3E10 patent granted in the U.S.Jul 12, 2017Other filingsASX
PAB Licences Deoxymab 3E10 - nanoparticle IP from YaleJun 12, 2017Other filingsASX
Finance UpdateApr 30, 2017Other filingsASX
Appendix 4C - Quarterly - 31 March 2017Apr 26, 2017Quarterly reportASX
Deoxymab 3E10 lead candidate confirmedApr 19, 2017Other filingsASX
Appendix 4D - Half Year Accounts - 31 December 2016Feb 22, 2017Interim reportASX
Appendix 4C - Quarterly - 31 December 2016Jan 17, 2017Quarterly reportASX
Appendix 4C - Quarterly - 30 September 2016Oct 28, 2016Quarterly reportASX
Appendix 4E and 2016 Annual ReportAug 30, 2016Annual reportASX
Appendix 4C - Quarterly - 30 June 2016Jul 27, 2016Quarterly reportASX
Appendix 4C - Quarterly - 31 March 2016Apr 20, 2016Quarterly reportASX
Publication on PAT-SM6 Combination TherapyApr 5, 2016Other filingsASX
Patrys Provides Update on CEO PositionMar 30, 2016Other filingsASX
Patrys Acquires Novel Assets from Yale UniversityMar 28, 2016Acquisition or disposalASX
Appendix 4D - Half Year Accounts - 31 December 2015Feb 24, 2016Interim reportASX
Appendix 4C - Quarterly - 31 December 2015Feb 11, 2016Quarterly reportASX
Appendix 4C - Quarterly - 30 September 2015Feb 10, 2016Quarterly reportASX